Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)

Recruiting

Phase 3

VDPHL01Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)

Sponsor:

Veradermics, Inc.

Code:

NCT07146022

Conditions

Androgenetic Alopecia (AGA)

Androgenetic Alopecia

AGA

Female Androgenetic Alopecia

Hair Loss

Eligibility Criteria

Sex: Female

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

VDPHL01 QD

Placebo

VDPHL01 BID

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-02. This information was provided to ClinicalTrials.gov by Veradermics, Inc. on 2025-08-28.